Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357761 | 0.82 | FFAR4 (0.46) | SLC6A4FFAR4LIPE | |
| SCHEMBL26552871 | 0.82 | ALDH1A1 (0.47) | EPHX2SLC6A4HSD11B1 | |
| SCHEMBL5019 | 0.82 | SLC6A4 (0.49) | EPHX2SLC6A4SLC6A3LIPE | |
| SCHEMBL1244796 | 0.80 | FFAR4 (0.50) | SLC6A4SLC6A3FFAR4LIPE | |
| SCHEMBL5919 | 0.80 | FFAR4 (0.41) | EPHX2FFAR4DRD3 | |
| SCHEMBL24227415 | 0.80 | USP2 (0.46) | EPHX2SLC6A4SLC6A3FFAR4LIPE | |
| SCHEMBL622213 | 0.79 | FFAR4 (0.46) | EPHX2FFAR4DRD3 | |
| SCHEMBL5301 | 0.79 | EPHX2 (0.42) | EPHX2SLC6A4SLC6A3FFAR4LIPE | |
| SCHEMBL621231 | 0.78 | EPHX2 (0.47) | EPHX2FFAR4 | |
| SCHEMBL747836 | 0.78 | EPHX2 (0.49) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |